Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Gaucher Therapy Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy RX501.190

    Enzyme Replacement Therapy for Gaucher Disease

    Customize your policy alerts

    Sign up for healthspring Policy RX501.190 alerts

    Get alerted when Policy RX501.190 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage of imiglucerase, taliglucerase alfa, and velaglucerase alfa for specified Gaucher disease manifestations in adults and pediatric patients, limited to FDA-labeled indications and subject to benefit plan and applicable state requirements.

    Policy Summary
    PayerHealthSpring
    PolicyEnzyme Replacement Therapy for Gaucher Disease
    Policy CodePolicy RX501.190
    Change TypeNew policy
    Effective DateJuly 21, 2026
    Next Review DateNot specified
    Key ActionWhen administering enzyme replacement therapy, closely monitor for hypersensitivity reactions and keep appropriate support measures and cardiopulmonary resuscitation equipment available.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical policy was established for enzyme replacement therapy used in the treatment of Gaucher disease.

    3Enzyme replacement therapies addressed
    Gaucher diseaseCovered disease focus
    4+Minimum age for taliglucerase alfa and velaglucerase alfa
    Not coveredOther indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3HCPCS codes listed

    Covered and Non-Covered Uses

    Imiglucerase (Cerezyme) initial therapy

    Imiglucerase may be considered medically necessary when the following condition is met.

    Covered indication: The individual is an adult or pediatric patient with non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease.

    Imiglucerase is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.

    Taliglucerase alfa (Elelyso) initial therapy

    Taliglucerase alfa may be considered medically necessary when the following conditions are met.

    Covered indication: The individual is 4 years of age or older and has a confirmed diagnosis of Type 1 Gaucher disease.Age ≥4 years

    Taliglucerase alfa is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.

    Velaglucerase alfa (VPRIV) initial therapy

    Velaglucerase alfa may be considered medically necessary when the following conditions are met.

    Covered indication: The individual is 4 years of age or older, has Type 1 Gaucher disease, and requires long-term enzyme replacement therapy.Age ≥4 years

    Velaglucerase alfa is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.

    Imiglucerase, taliglucerase alfa, and velaglucerase alfa are considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.

    HCPCS Codes

    HCPCS CodesHCPCS
    J1786HCPCS code J1786
    J3060HCPCS code J3060
    J3385HCPCS code J3385

    Provider Guidance and Coverage Limitations

    Documentation Required

    Monitor for hypersensitivity reactions

    When enzyme replacement therapy is administered, closely monitor the individual for hypersensitivity reactions, including anaphylaxis. Ensure appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, are readily available.

    Denial Risk

    Use only for FDA-approved indications

    Coverage may be denied when the requested enzyme replacement is used for an indication other than its specified FDA-approved Gaucher disease indication. The therapies are considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.

    Note

    Gaucher Disease Overview

    Gaucher disease is an inherited lysosomal storage disorder caused by deficient glucocerebrosidase, leading to accumulation of glucocerebroside in macrophages and organs including the bone marrow, spleen, and liver. Type 1 disease primarily causes visceral, hematologic, and bone manifestations without brain involvement; Type 2 is associated with severe neurologic disease; and Type 3 combines systemic disease with some neurologic involvement. Enzyme replacement therapy replenishes glucocerebrosidase to reduce substrate accumulation and is used primarily for non-central nervous system manifestations of Type 1 or Type 3 disease.

    Disease Types and Policy Terminology

    Gaucher disease Type 1
    FormThe most common form of Gaucher disease in Western countries.
    Characteristic manifestationsSpleen and liver enlargement, bone problems, bleeding problems related to low platelets or abnormal clotting, and anemia.
    Neurologic statusBrain development is normal.
    Gaucher disease Type 2
    FormA rare form of Gaucher disease involving severe neurologic, or brain-stem, abnormalities.
    PrognosisThe disease is usually fatal within the first 2 years.
    Treatment status

    Drug-Specific Initial Therapy

    Imiglucerase (Cerezyme)

    Imiglucerase may be considered medically necessary for the following diagnosis.

    Imiglucerase eligibility: The individual is an adult or pediatric patient with non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease.

    Imiglucerase is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.

    Taliglucerase alfa (Elelyso)

    Taliglucerase alfa may be considered medically necessary when the following diagnosis and age requirement are met.

    Taliglucerase alfa eligibility: The individual is 4 years of age or older and has a confirmed diagnosis of Type 1 Gaucher disease.Age ≥4 years

    Taliglucerase alfa is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.

    Administration Setting and Infusion Requirements

    Billing Rule

    Administer in a monitored infusion setting

    Administer enzyme replacement therapy in an infusion center with close monitoring for hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures and cardiopulmonary resuscitation equipment must be readily available.

    Note

    Clinical trial administration schedule

    In the described clinical trials, Elelyso and VPRIV were administered intravenously every other week.

    • Elelyso: IV dosage administered every other week.
    • VPRIV: administered IV over 60 minutes every other week in the trials.
    Policy Summary
    PayerHealthSpring
    PolicyEnzyme Replacement Therapy for Gaucher Disease
    Policy CodePolicy RX501.190
    Change TypeNew policy
    Effective DateJuly 21, 2026
    Next Review DateNot specified
    Key ActionWhen administering enzyme replacement therapy, closely monitor for hypersensitivity reactions and keep appropriate support measures and cardiopulmonary resuscitation equipment available.
    SourceLink
    On This Page
    Covered and Non-Covered UsesHCPCS CodesProvider Guidance and Coverage LimitationsGaucher Disease OverviewDisease Types and Policy TerminologyDrug-Specific Initial TherapyAdministration Setting and Infusion Requirements

    Verify benefit plan limitations

    Coverage may be limited or excluded by the member’s benefit plan, summary plan description, or contract. If a Medical Policy conflicts with the member’s benefit plan, summary plan description, or contract, the benefit plan, summary plan description, or contract governs.

    Currently untreatable because of severe, irreversible brain damage.
    Gaucher disease Type 3
    FormA rare form in the United States and Europe and the most common form worldwide.
    Systemic manifestationsCauses the same symptoms as Type 1, including spleen and liver enlargement, bone problems, bleeding problems, and anemia.
    Neurologic manifestations and severityIncludes some neurologic involvement and has a severity between Types 1 and 2.
    Enzyme replacement therapy
    Treatment approachTreatment that replaces deficient glucocerebrosidase with enzyme-replacement therapy.
    Therapeutic purposeHelps break down accumulated glucocerebroside and minimize symptoms and effects on organs.
    Clinical focusUsed primarily for non-central nervous system manifestations of Type 1 or Type 3 Gaucher disease; it is not effective for neurologic symptoms.
    % BW
    Abbreviation% BW
    MeaningPercentage of body weight.
    Example of useUsed to report spleen volume and liver volume measurements.
    MN
    AbbreviationMN
    MeaningMultiples of normal.
    Example of useUsed to report spleen volume and liver volume measurements relative to normal.
    SD
    AbbreviationSD
    MeaningStandard deviation.
    Example of useUsed in the efficacy table to report the variability of clinical parameter measurements as mean (SD).

    Velaglucerase alfa (VPRIV)

    Velaglucerase alfa may be considered medically necessary when the following diagnosis, age, and treatment requirements are met.

    Velaglucerase alfa eligibility: The individual is 4 years of age or older, has Type 1 Gaucher disease, and requires long-term enzyme replacement therapy.Age ≥4 years

    Velaglucerase alfa is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.